JERUSALEM, Israel, April 10 /PRNewswire-FirstCall/ -- IDenta Corp. today released a recap of three Federal meetings its CEO attended during his recent U.S. visit.
The memorandum adds to two previously reported activities, the signing of Venable LLC, www.venable.com, to represent the company’s Federal Government lobbying program, and the signing of an agreement with APH Group, www.APHGroup.us, to lead IDenta’s expansion into the U.S. civilian marketplace.
“I couldn’t be more happy about the results of my recent U.S. visit,” reported Identa (symbol IDTA) CEO Yaccov Shoham. “While in Washington D.C., I attended three very valuable meetings with Venable representatives that greatly increased the visibility and credibility of IDenta. Then at the meeting with APH Group in Savannah, numerous marketing opportunities were exposed that we need to immediately explore.”
The latest recap lists the following events:
1. Meeting with U.S. Drug Enforcement Agency laboratory directors who agreed to test IDenta’s products on a broader scale among DEA agents.
2. Made a presentation at the Law Enforcement Caucus on Capital Hill.
3. Made a presentation at the Methamphetamine Caucus on Capital Hill.
“Our presentation was especially timely at the Meth Caucus, where The Combat Methamphetamine Epidemic Act, the first-ever comprehensive anti-meth legislative action, was recently signed into law,” recounted Shoham.
(See: www.house.gov/larsen/meth/press_release_20060302.shtml)
About IDenta
IDenta Corporation is one of the world’s leading providers of proprietary on-site drug detection kits for governmental, professional and civilian use. Information concerning IDenta’s business plan and product line, including rapid test kits (substance only) for the detection of marijuana, hashish, ecstasy, cocaine, crack, heroin and methamphetamines may be found at www.IDenta.biz and www.drugsdetector.com
For Investor Relations, lobbying interests or information concerning IDenta’s products internationally contact: Yaacov Shoham, IDenta Corp., CEO Tel: +972-52-6554487, +972-8-9716874 Fax: +972-8-9716875 fpi@drugsdetector.com For Investor Relations in the United States contact: Randy Jacobs, SITCOM LLC IDentaNews@sitcomllc.com +1-800-316-9437
Certain of the statements contained herein may be, within the meaning of the federal securities laws, “forward-looking statements” that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management’s expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.
IDenta Corp.
CONTACT: For Investor Relations, lobbying interests or informationconcerning IDenta’s products internationally contact: Yaacov Shoham, IDentaCorp., CEO, Tel: +972-52-6554487, +972-8-9716874, Fax: +972-8-9716875,fpi@drugsdetector.com. For Investor Relations in the United States contact:Randy Jacobs, SITCOM LLC, IDentaNews@sitcomllc.com, +1-800-316-9437
